Last $0.40 USD
Change Today 0.00 / 0.00%
Volume 60.7K
As of 8:10 PM 08/21/14 All times are local (Market data is delayed by at least 15 minutes).

cytomedix inc (CMXI) Snapshot

Open
$0.40
Previous Close
$0.40
Day High
$0.40
Day Low
$0.39
52 Week High
12/4/13 - $0.68
52 Week Low
11/13/13 - $0.33
Market Cap
49.8M
Average Volume 10 Days
137.1K
EPS TTM
$-0.25
Shares Outstanding
124.4M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for CYTOMEDIX INC (CMXI)

Related News

No related news articles were found.

cytomedix inc (CMXI) Related Businessweek News

No Related Businessweek News Found

cytomedix inc (CMXI) Details

Cytomedix, Inc. operates as a regenerative therapies company in the United States and internationally. The company manufactures and distributes the AutoloGel System, a point of care device for the production of a platelet based bioactive therapy derived from the patient’s own blood; and Angel Concentrated Platelet Rich Plasma System, a multi-functional cell separation device, which produces concentrated platelet rich plasma for use in the operating room and clinic, as well as in a range of orthopedic and cardiovascular indications. Its Angel product line also includes ancillary products, such as phlebotomy and applicator supplies; and activAT, which produces autologous thrombin serum from platelet poor plasma. Cytomedix, Inc. sells its products through direct sales representatives and distributors. The company was formerly known as Autologous Wound Therapy, Inc. and changed its name to Cytomedix, Inc. in 2000. Cytomedix, Inc. was founded in 1987 and is headquartered in Gaithersburg, Maryland.

cytomedix inc (CMXI) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $467.3K
Executive Chairman
Total Annual Compensation: $100.0K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $185.3K
Compensation as of Fiscal Year 2013.

cytomedix inc (CMXI) Key Developments

Cytomedix Partners with Net Health to Expand CED Data Collection Capabilities to Approximately 400 Additional Wound Care Centers

Cytomedix announced that it has partnered with Net Health to develop functionality in Net Health's WoundExpert software that enables collection of patient data for the company's Coverage with Evidence Development program. Under the arrangement, Cytomedix and Net Health will collaborate to develop functionality within the WoundExpert software to allow clinics to identify patients that may qualify for the AutoloGel CED program and track the necessary data points for those patients. Additionally, Cytomedix and Net Health will jointly market the benefits of CED data collection and highlight the key points of CED enrollment to current WoundExpert users. The Agreement will focus on approximately 400 Net Health wound clinic customers in the United States.

Cytomedix, Inc. Announces Unaudited Consolidated Earnings Results for Second Quarter and Six Months Ended June 30, 2014

Cytomedix, Inc. announced unaudited consolidated earnings results for second quarter and six months ended June 30, 2014. For the quarter, the company reported total revenues of $2,326,104, loss from operations of $9,822,490, loss before provision for income taxes of $11,315,993, net loss to common stockholders of $11,320,638 or $0.09 per basic and diluted share compared to the total revenues of $2,423,898, loss from operations of $4,661,731, loss before provision for income taxes of $5,031,760, net loss to common stockholders of $5,036,650 or $0.05 per basic and diluted share for the same quarter a year ago. The decrease in revenue was primarily due to lower Angel product sales of $0.5 million, offset by an increase in royalty revenue of $0.3 million and license fee revenue of $0.1 million. The decrease in product sales was primarily due to a reduction in Angel average selling price under the terms of the Arthrex Agreement. AutoloGel(TM) sales for the quarter were $0.1 million. For the six months period, the company reported total revenues of $4,172,033, loss from operations of $14,472,650, loss before provision for income taxes of $16,944,261, net loss to common stockholders of $16,953,551 or $0.15 per basic and diluted share compared to the total revenues of $4,741,199, loss from operations of $9,664,941, loss before provision for income taxes of $10,365,439, net loss to common stockholders of $10,375,219 or $0.1 per basic and diluted share for the same period a year ago.

Cytomedix, Inc. to Report Q2, 2014 Results on Aug 14, 2014

Cytomedix, Inc. announced that they will report Q2, 2014 results at 5:00 PM, Eastern Standard Time on Aug 14, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CMXI:US $0.40 USD 0.00

CMXI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Aastrom Biosciences Inc $3.64 USD -0.07
Baxter International Inc $75.80 USD +0.55
Cesca Therapeutics Inc $1.32 USD +0.02
View Industry Companies
 

Industry Analysis

CMXI

Industry Average

Valuation CMXI Industry Range
No financial data is available for CMXI.
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CYTOMEDIX INC, please visit www.cytomedix.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.